ScreenerHero

ENTX Entera Bio Ltd.

NAS · US · Healthcare · Biotechnology · enterabio.com
2.510USD-0.79%Mkt Cap: 436.32M $P/E: —

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase I…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap436.32M USD
Enterprise Value427.16M USD
Revenue (TTM)0 USD
Gross Profit0 USD
Net Income (TTM)-11.44M USD
Revenue/Share0.00 USD
Last Price2.510 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees20
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.60
PEG—
EV/EBITDA-29.73
EV/Revenue—
P/SInfinity
P/B17.21
EPS (TTM)-0.35
EPS (Forward)-0.55
52W Range
0.910049% of range4.200
52W High4.200 USD
52W Low0.9100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-27235.71%
ROE-87.31%
ROA-71.53%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-7.37M USD
CapEx (TTM)107.00K USD
FCF Margin—
FCF Yield-1.53%
Net Debt-10.88M USD
Net Debt/EBITDA0.76
Balance Sheet
Debt/Equity0.04
Current Ratio8.98
Quick Ratio5.42
Book Value/Sh0.15 USD
Cash/Share0.07 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)9.750 USD
Upside (mean)+288.4%
Target Range9.000 USD – 11.00 USD
9.000+288.4% to mean11.00
# Analysts4
Ownership
Shares Out.173.83M
Float126.47M
Insiders5.47%
Institutions34.11%
Short Interest
Short Ratio3.5d
Short % Float0.77%
Short % Out.0.74%
Shares Short1.28M
Short (prev mo.)956.76K
Technical
SMA 502.967 (-15.4%)
SMA 2001.805 (+39.1%)
Beta1.41
S&P 52W Chg16.45%
Avg Vol (30d)466.70K
Avg Vol (10d)549.84K
Technical Indicators
RSI (14)37.1
MACD-0.0580
MACD Signal-0.0138
MACD Hist.-0.0442
BB Upper3.087 USD
BB Middle2.806 USD
BB Lower2.525 USD
BB Width20.02%
ATR (14)0.2013 USD
Vol Ratio (20d)1.33x